NEW YORK (GenomeWeb) – Caris Life Science said today that it will use informatics solutions offered by GenoSpace to support its oncology profiling services.
Specifically, Caris said it will use GenoSpace's population analytics offerings to analyze data from its tumor profiling service, Caris Molecular Intelligence. Caris will also leverage GenoSpace's analytics architecture expertise to mine data in Caris Registry, its database of clinicopathologic and outcome variables collected from consenting patients.
"The combination of GenoSpace's population analytics offerings and Caris' unprecedented database and registry will provide a unique opportunity for discovery of new biomarkers that can predict a wide range of clinically relevant endpoints and ultimately lead to improvements in the quality and cost of patient care," John Quackenbush, GenoSpace's CEO, said in a statement.
Financial and other terms of the agreement were not disclosed.